Company Focus
Lonza
Latest Lonza News
Biotechnology
German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza, have announced a collaboration. 7 April 2025
Cell & Gene Therapy News
Insights
Company Spotlight
A clinical-stage biotech company advancing next generation, potentially curative cell therapies for cancer patients.
Latest News & Features of interest to Lonza
Biotechnology
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
Biotechnology
Galapagos said on Tuesday that its chief financial officer and chief operating officer Thad Huston will leave the company on August 1, 2025, to return to the USA for personal and professional reasons. 15 April 2025
Biotechnology
US sequencing firm PacBio is cutting jobs and reducing spending across its business as it braces for the financial impact of new global tariffs and growing uncertainty around federal research funding. 14 April 2025
Biotechnology
US biotech Cartesian Therapeutics has reported that patients with generalized myasthenia gravis (gMG) continued to experience lasting symptom relief 12 months after treatment with its investigational cell therapy Descartes-08, according to new data from a mid-stage trial. 9 April 2025
Biotechnology
German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza, have announced a collaboration. 7 April 2025
Biotechnology
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 6 April 2025
Biotechnology
Australian biotech major CSL Limited subsidiary CSL Behring today announced that it has successfully concluded negotiations in Germany with the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) resulting in national reimbursement of Hemgenix (etranacogene dezaparvovec). 3 April 2025
Biotechnology
The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' gene therapy, Elevidys (delandistrogene moxeparvovec-rokl), for Duchenne muscular dystrophy (DMD). 3 April 2025
Biotechnology
US biotech Artis BioSolutions has officially launched with the acquisition of Landmark Bio, a translational development and manufacturing group formed through an alliance of academic and industry stakeholders. 2 April 2025
Biotechnology
US biotech AIRNA has raised $155 million in series B funding to advance its lead RNA-editing therapy into human trials and expand its pipeline of genetic medicines targeting both rare and common diseases. 1 April 2025
Latest In Brief for Lonza
Biotechnology
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France. 8 February 2025
Latest Cell & Gene Therapy Ones To Watch News
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
29 March 2025
11 March 2025
Cell & Gene Therapy Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze